Chronic lymphocytic leukemia-associated immune thrombocytopenia treated with rituximab: A retrospective study of 21 patients

European Journal of Haematology

Volumn 85, Issue 6, 2010, Pages 502-507

  D'Arena, Giovanni ^a   Capalbo, Silvana ^b   Laurenti, Luca ^c   Del Poeta, Giovanni ^d   Nunziata, Giuseppe ^e   Deaglio, Silvia ^f   Spinosa, Giuseppina ^b   Tarnani, Michela ^c   De Padua, Laura ^c   Califano, Catello ^g   Ferrara, Felicetto ^e   Cascavilla, Nicola ^a  

^a CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^b OSPEDALI RIUNITI   (Italy)

^c CATHOLIC UNIVERSITY   (Italy)

^d UNIVERSITY OF ROME TOR VERGATA   (Italy)

^e CARDARELLI HOSPITAL   (Italy)

^f UNIVERSITY OF TURIN   (Italy)

^g Umberto I Hospital   (Italy)

Author keywords

Chronic lymphocytic leukemia; Immune thrombocytopenia; Rituximab

Indexed keywords

CYCLOPHOSPHAMIDE; FLUDARABINE; IMMUNOGLOBULIN; METHYLPREDNISOLONE; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ARTICLE; AUTOIMMUNE THROMBOCYTOPENIA; BRONCHOPNEUMONIA; CHILL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; DISEASE ASSOCIATION; DRUG DOSE INCREASE; DRUG MEGADOSE; DRUG WITHDRAWAL; FEMALE; FEVER; HEMOLYSIS; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOLOGIC FACTORS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 78349285119     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2010.01527.x     Document Type: Article

References (28)

1. Diehl LF, Ketchum LH. Autoimmune disease and chronic lymphocytic leukemia: autoimmune hemolytic anemia, pure red cell aplasia, and autoimmune thrombocytopenia. Semin Oncol 1998;25:80-97.
2. Hamblin TJ. Autoimmune complications of chronic lymphocytic leukemia. Semin Oncol 2006;33:230-9.
3. D'Arena G, Cascavilla N. Chronic lymphocytic leukemia-associated autoimmune hemolytic anemia. Leuk Lymphoma 2007;48:1072-80.
4. Dearden C Disease-specific complications of chronic lymphocytic leukemia. Am Soc Hematol Educ Program 2008;450-6.
5. D'Arena G, Cascavilla N. Chronic lymphocytic leukemia-associated pure red cell aplasia. Int J Immunopathol Pharmacol 2009;22:279-86.
6. Visco C, Ruggeri M, Evangelista ML, Stasi R, Zanotti R, Giaretta I, Ambrosetti A, Madeo D, Pizzolo G, Rodeghiero F. Impact of immune thrombocytopenia on the clinical course of chronic lymphocytic leukemia. Blood 2008;111:1110-6.
7. Rai JR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS. Clinical staging of chronic lymphocytic leukemia. Blood 1975;46:219-34.
8. Binet JL, Auquier A, Dighiero G, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate analysis. Cancer 1981;48:198-204.
9. Hedge UP, Wilson WH, White T, Cheson BD. Rituximab treatment of refractory fludarabine-associated immune thrombocytopenia in chronic lymphocytic leukemia. Blood 2002;100:2260-2.
10. Zaja F, Vianelli N, Sperotto A, Patriarca F, Tani M, Marin L, Tiribelli M, Candoni A, Baccarini M, Fanin R. Anti-CD20 therapy for chronic lymphocytic leukemia-associated autoimmune diseases. Leuk Lymphoma 2003;44:1951-5.
11. Aleem A. Rituximab therapy in a patient with autoimmune hemolytic anemia and immune thrombocytopenia with chronic lymphocytic leukemia. Ann Saudi Med 2008;28:382-5.
12. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998;16:2825-33.
13. Tam CS, O'Brien S, Wierda W, Kantarjian H, Wen S, Do KA, Thomas DA, Cortes J, Lerner S, Keating MJ. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 2008;112:975-80.
14. D'Arena G, Laurenti L, Capalbo S, et al. Rituximab therapy for chronic lymphocytic leukemia-associated autoimmune hemolytic anemia. Amer J Hematol 2006;81:598-602.
15. D'Arena G, Vigliotti ML, Dell'Olio M, Villa MR, Mantuano S, Scalzulli PR, La Sala A, Abbadessa A, Mastrullo L, Cascavilla N. Rituximab to treat chronic lymphoproliferative disorders-associated pure red cell aplasia. Eur J Hematol 2009;82:235-9.
16. Zaja F, Baccarani M, Mazza P, et al. Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia. Blood 2010;115:2755-62.
17. Edwards JCW, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, Stevens RM, Shaw T. Efficacy of B-cell-targeted therapy with rheumathoid arthritis. N Engl J Med 2004;350:2572-81.
18. Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 2009;113:2386-93.
19. Provan D, Stasi R, Newland AC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 2010;115:168-86.
20. Liebman HA. Recognizing and treating secondary immune thrombocytopenic purpura associated with lymphoproliferative disorders. Semin Hematol 2009;46(Suppl 2):533-6.
21. D'Arena G, Musto P, Cascavilla N, Dell'Olio M, Di Renzo N, Carotenuto M. Quantitative flow cytometry for the differential diagnosis of leukemic B-cell chronic lymphoproliferative disorders. Am J Hematol 2000;64:275-81.
22. Taylor RP, Linforder MA. Immunotherapeutic mechanisms of anti-CD20 monoclonal antibodies. Curr Opin Immunol 2008;20:444-9.
23. Hall AM, Vickers MA, McLeod E, Barker RN. Rh autoantigen presentation to helper T cells in chronic lymphocytic leukemia by malignant B cells. Blood 2005;105:2007-15.
24. Visco C, Giaretta I, Ruggeri M, Madeo D, Tosetto A, Rodeghiero F. Un-mutated IgVH in chronic lymphocytic leukemia is associated with a higher risk of immune thrombocytopenia. Leukemia 2007;21:1092-3.
25. Tobin G, Thunberg U, Karlsson K, et al. Subsets with restricted immunoglobulin gene rearrangement features indicate a role for antigen selection in the development of chronic lymphocytic leukemia. Blood 2004;104:2885-97.
26. Messmer BT, Albesiano E, Efremov DG, et al. Multiple distinct sets of stereotyped antigen receptors indicate a key role for antigen in promoting chronic lymphocytic leukemia. J Exp Med 2004;200:519-25.
27. Gupta N, Kavuru S, Patel D, Janson D, Driscoll N, Ahmed S, Rai KR. Rituximab-based chemotherapy for steroid-refractory autoimmune hemolytic anemia of chronic lymphocytic leukemia. Leukemia 2002;16:2092-5.
28. Bower DA, Call TG, Shanafelt TD, Kay NE, Schwager SM, Reinalda MS, Rabe KG, Slager SL, Zent CS. Treatment of autoimmune cytopenia complicating progressive chronic lymphocytic leukemia/small lymphocytic lymphoma with rituximab, cyclophosphamide, vincristine, and prednisone. Leuk Lymphoma 2010;51:620-7.